Tracked shipping to the Netherlands for just € 7. Prices include 9% BTW and new EU € 3 customs duty. No hidden fees. 

Ship to
Netherlands
0
  • argentina
  • chile
  • colombia
  • españa
  • méxico
  • perú
  • estados unidos
  • internacional

Select your country

Americas

Europe

Rest of the world

portada Targeting the DNA Damage Response for Anti-Cancer Therapy
Type
Physical Book
Publisher
Language
English
Pages
401
Format
Paperback
Dimensions
23.4 x 15.6 x 2.1 cm
Weight
0.58 kg.
ISBN13
9783030093365

Targeting the DNA Damage Response for Anti-Cancer Therapy

Pollard, John ; Curtin, Nicola (Author) · Humana · Paperback

Targeting the DNA Damage Response for Anti-Cancer Therapy - Pollard, John ; Curtin, Nicola

Cheaper New Book Imported to Netherlands
Delivery: 13 Aug - 20 Aug Shipping: 13 to 17 business days.
218,85 €
Faster New Book Imported to Netherlands
Delivery: 03 Aug - 05 Aug Shipping: 5 to 6 business days.
268,48 €
Import costs and 9% BTW included in the price ✅
218,85 €

Synopsis "Targeting the DNA Damage Response for Anti-Cancer Therapy"

Over the past decade a complex role for DNA damage response (DDR) in tumorigenesis has emerged. A proficient DDR has been shown to be a primary cause for cellular resistance to the very many DNA damaging drugs, and IR, that are widely used as standard-of-care across multiple cancer types. It has also been shown that defects in this network, predominantly within the ATM mediated signaling pathway, are commonly observed in cancers and may be a primary event during tumorigenesis. Such defects may promote a genomically unstable environment, facilitating the persistence of mutations, any of which may provide a growth or survival advantage to the developing tumor. In addition, these somatic defects provide opportunities to exploit a reliance on remaining repair pathways for survival, a process which has been termed synthetic lethality. As a result of all these observations there has been a great interest in targeting the DDR to provide anti-cancer agents thatmay have benefit as monotherapy in cancers with high background DNA damage levels or as a means to increase the efficacy of DNA damaging drugs and IR. In this book we will review a series of important topics that are of great interest to a broad range of academic, industrial and clinical researchers, including the basic science of the DDR, its role in tumorigenesis and in dictating response to DNA damaging drugs and IR. Additionally, we will focus on the several proteins that have been targeted in attempts to provide drug candidates, each of which appear to have quite distinct profiles and could represent very different opportunities to provide patient benefit.

Customers reviews

Frequently Asked Questions about the Book

All books in our catalog are Original.
The book is written in English.
The binding of this edition is Paperback.

Questions and Answers about the Book

Do you have a question about the book? Login to be able to add your own question.

Opinions about Bookdelivery

More customer reviews